Evidence map›Paper›PMID 30547388›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2019

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.

Keith Bowering, Helena W Rodbard, David Russell-Jones, Bruce Bode, Stewart Harris, Milivoj Piletic, Simon Heller, Vincent Woo, Vinay Babu, Claus Dethlefsen and 1 more

3 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01819129 phase3completednot on this map

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

TypeinterventionalSponsorNovo Nordisk A/SRan2013 to 2015Enrolled881ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsFaster-acting insulin aspart, Insulin aspart, Insulin glargine
NCT01831765 phase3completednot on this map

Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes

TypeinterventionalSponsorNovo Nordisk A/SRan2013 to 2015Enrolled1,290ConditionsDiabetes, Diabetes Mellitus, Type 1ArmsFaster-acting insulin aspart, insulin detemir, insulin aspart
NCT01850615 phase3completednot on this map

Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes

TypeinterventionalSponsorNovo Nordisk A/SRan2013 to 2014Enrolled323ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsFaster-acting insulin aspart, basal insulin
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 6 countries.

Keith BoweringDivision of Endocrinology and Metabolism, University of Alberta, Edmonton, AB, Canada. keith.bowering@ualberta.ca.ORCID http://orcid.org/0000-0002-0075-0624
Helena W RodbardEndocrine and Metabolic Consultants, Rockville, MD, USA.
David Russell-JonesDiabetes and Endocrinology, Royal Surrey County Hospital, Guildford, UK.
Bruce BodeAtlanta Diabetes Associates, Atlanta, GA, USA.
Stewart HarrisWestern University, London, ON, Canada.
Milivoj PileticGeneral Hospital, Novo Mesto, Slovenia.
Simon HellerAcademic Unit of Diabetes, Endocrinology and Metabolism, University of Sheffield, Sheffield, UK.
Vincent WooSection of Endocrinology and Metabolism, University of Manitoba, Winnipeg, MB, Canada.
Vinay BabuNovo Nordisk A/S, Søborg, Denmark.
Claus DethlefsenNovo Nordisk A/S, Søborg, Denmark.
Chantal MathieuClinical and Experimental Endocrinology, University Hospital Leuven, Catholic University of Leuven, Leuven, Belgium.
Novo Nordisk (Denmark) · DKAtlanta Diabetes Associates · USKU Leuven · BERoyal Surrey County Hospital · GBSchool of Business and Management Novo Mesto · SIUniversity of Alberta · CAUniversity of Manitoba · CAUniversity of Sheffield · GBWestern University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe aim of this study was to investigate the association between baseline characteristics [HbA1c and body mass index (BMI)] and the effect of mealtime fast-acting insulin aspart (faster aspart) relative to insulin aspart (IAsp) or basal-only insulin therapy on several efficacy and safety outcomes in people with diabetes.

methodsPost hoc analysis of three randomised phase 3a trials in people with type 1 diabetes (T1D; onset 1) and type 2 diabetes (T2D; onset 2 and 3). Participants (N = 1686) were stratified according to baseline BMI (< 25 kg/m

resultsIn participants with T2D, the estimated treatment difference for change in HbA1c was similar for all BMI and HbA1c subgroups. No major differences between treatments were observed in risk of overall hypoglycaemia or insulin dose across subgroups. In participants with T1D, change in HbA1c was similar across BMI and HbA1c subgroups, and no major differences between treatments were observed for severe or blood glucose-confirmed hypoglycaemia across subgroups. Total daily insulin dose (U/kg) was similar across all baseline HbA1c groups and the BMI < 25 kg/m

conclusionsIn participants with T1D and T2D, treatment differences (for change in HbA1c and overall hypoglycaemia) between mealtime faster aspart and insulin comparators were similar to the corresponding overall analysis across baseline HbA1c and BMI subgroups. The finding of a lower total daily insulin dose in participants with obesity (BMI > 30 kg/m

trial registrationClinicalTrials.gov NCT01831765 (onset 1); NCT01819129 (onset 2); NCT01850615 (onset 3).

fundingNovo Nordisk A/S, Søborg, Denmark.

Indexed as

Diabetes mellitus, type 1Diabetes mellitus, type 2Haemoglobin A, glycosylatedIndex, body massInsulin aspartOutcome, treatment

Identifiers

PMID30547388
PMCPMC6349278
OpenAlexW2904126392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.